Condition: Liver Transplantation · Immunosuppression · Neurotoxicity · Sponsor: University of British Columbia
This is a randomized open label study in de novo liver transplant recipients that aims to compare the risk of tacrolimus induced tremors with once daily extended-release formulation, Envarsus, versus the twice daily immediate-release formulation. Both formulations of tacrolimus are currently approved for the prevention of rejection in liver transplant patients.
This description comes directly from the study's public registry record.
Trana Hussaini · 6043284930 · trana.hussaini@vch.ca
Eric Yoshida, MD · 604-872-9858 · eric.yoshida@vch.ca
Always discuss trial participation with your own doctor first.
| Vancouver General Hospital | Vancouver, British Columbia, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05089604